Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.3617 +0.0116 (+3.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) shares moved upwards by 33.66% to $4.3 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 87.6... 
Via Benzinga
Bluebird Bio's Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold
Shares for Bluebird Bio Inc (NASDAQ: BLUE) is hovering at a 52-week low after the FDA placed a clinical hold on clinical studies of elivaldogene autotemcel (... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 30.38% to $2.36 during Monday's pre-market session. The company's market cap stands at $61.9 million. The... 
Via Benzinga
Recap: bluebird bio Q2 Earnings
Shares of bluebird bio (NASDAQ:BLUE) moved higher by 0.9% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 852.78... 
Via Benzinga
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
From bluebird bio, Inc.
Via Business Wire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR).... 
Via Benzinga
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?
After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain. 
Via The Motley Fool
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
From bluebird bio, Inc. and Resilience
Via Business Wire
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
From bluebird bio, Inc.
Via Business Wire
Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?
Neither healthcare stock has performed well so far this year. 
Via The Motley Fool
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC
European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefit-risk of Bluebird Bio Inc's (NASDAQ: BLUE)... 
Via Benzinga
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
From bluebird bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021
Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE: 
Via Benzinga
Will This 2020 Biotech IPO Crush the Market This Year?
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Product Safety Securities Market
Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?
With safety concerns allayed, the company is ready to restart clinical trials of key therapies. 
Via The Motley Fool
Exposures Product Safety
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
From bluebird bio, Inc.
Via Business Wire
Bluebird bio Can Restart Halted Clinical Trials
The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia. 
Via The Motley Fool
Exposures Product Safety
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
Bluebird Bio Pops As FDA Allows In-Human Gene Therapy Testing To Resume
The FDA removed a hold barring Bluebird Bio from testing its blood-disease gene therapies in people on Monday, and BLUE stock surged. 
Via Investor's Business Daily
Exposures Product Safety
FDA Gives Signal to Halted Bluebird Bio's Gene Therapy Trials In Sickle Cell Disease, Thalassemia
The FDA has lifted the clinical hold on Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of Bluebird Bio Inc's (NASDAQ: BLUE) LentiGlobin for sickle cell... 
Via Benzinga
Exposures Product Safety
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
From bluebird bio
Via Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Is bluebird bio a Buy for Summer 2021?
With the stock down 54% over the past year, will investors be catching a falling knife if they buy now? 
Via The Motley Fool
Bluebird bio's Neurological Disorder Gene Therapy Wins CHMP Backing for Approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.